The global tuberculosis therapeutics market size is expected to reach $2.99B, expanding at a CAGR of 5.09% from 2023 to 2030, according to a report from Research & Markets.
The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis. According to the World Health Organization's 2022 Global TB report, an estimated 10.6 million people suffered in 2021, a 4.5% increase from 2020, and has accounted for the death of around 1.6 million people. This high rate of mortality demonstrates an unmet need for cost-effective and efficient drugs in the market.
The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021. This is the first time in the past few years that an increase in the number of people suffering from TB and DR-TB has been reported.
The COVID-19 pandemic in 2021 has disrupted many services, including TB care. However, the impact has been severely seen in the TB response. Moreover, because the current vaccine, known as BCG, is over 100 years old and has limited efficacy in adults, the ability to control transmission is limited. Thus, creating business opportunities for therapeutics.
The rising incidence of multidrug-resistant and extensively drug-resistant tuberculosis has further propelled the demand for providing appropriate therapeutics.